Catalyst Pharmaceutical Partners Provides Update on Firdapse Progress

barbara.lempert CORAL GABLES, Fla., June 27, 2013 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development ...

Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR

barbara.lempert ROCKVILLE, Md., June 27, 2013 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on June 26, 2013 the Company received a Paragraph ...

SNBL USA Announces Appointment of Dr. Michael Templin as Field Technical Director

barbara.lempert (Everett, Wash., June 27, 2013) – SNBL USA, the experts in primate research, is pleased to announce the appointment of Michael Templin, PhD, DABT, as field technical ...

Innovus Appoints Robert E. Hoffman to Newly Formed Business and Finance Advisory Board

barbara.lempert        Brings Broad Experience in Biopharmaceutical Finance LA JOLLA, Calif., June 27, 2013 (GLOBE NEWSWIRE) — Innovus Pharmaceuticals Inc., (“Innovus ...

Pergamum reports positive follow-up data from a Phase II clinical trial of PXL-01 for prevention of post-surgical adhesions

barbara.lempert STOCKHOLM – June 27, 2012. Pergamum AB announced today that several end-points were met in a randomized Phase II trial of PXL-01 for prevention of post-surgical adhesions. ...

Tweets of the day, 6/27/2013

chris.truelove by Christiane Truelove (chris.truelove@ubm.com) Not so surprisingly, Novo Nordisk has decided to suspend promotional activities with Paula Deen in the wake of the continued ...

Hermes Pharma Completes Successful Routine FDA Inspection of Production Facility

barbara.lempert Inspection Opens Door for Hermes Pharma to Increase Production of User-friendly Solid Oral Dosage Forms for the US PULLACH, Germany, June 26, 2013 — Hermes ...

Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman

barbara.lempert Oxford, UK, June 26th 2013: Oxford BioTherapeutics (OBT), a global biotechnology company developing first-in-class, antibody-based cancer medicines to fulfil unmet ...

Michel Spagnol appointed president and CEO of Novasep

barbara.lempert Pompey, France, June 26, 2013 – Novasep, a leading provider of purification-based manufacturing solutions for life sciences molecules, today announces ...

Chimerix to Join Russell Indexes on June 28, 2013

barbara.lempert DURHAM, N.C., June 25, 2013 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet ...

Omthera Pharmaceuticals Announces Termination Of Antitrust Waiting Period

barbara.lempert PRINCETON, N.J., June 27, 2013 /PRNewswire/ — Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) today announced that, as of June 26, 2013, the Federal Trade Commission ...

Veloxis Announces Positive Results of 3002 Study: LCP-Tacro Meets Primary Efficacy and Safety Endpoints in de Novo Kidney Transplant Patients

barbara.lempert – LCP-Tacro™, once-daily, demonstrated non-inferiority to Prograf®, twice-daily, based on the composite endpoint of treatment failure at one year (LCP-Tacro™ ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS